FDA Publishes Revised Draft Guidances Aimed at Generic Versions of Peptide Drugs, Including GLP-1 Medicines

The U.S. Food and Drug Administration has taken a technical but potentially consequential step toward generic versions of peptide drugs, a category that now includes the blockbuster GLP-1 medicines used for weight loss and type 2 diabetes. On July 28, 2026, the agency announced 17 revised draft product-specific guidances that tell companies how to prove a proposed generic peptide is equivalent to the brand-name product. The notice appeared in the Federal Register on July 29, 2026.

The move does not approve any generic drug and does not set a timeline for one. It is a set of scientific recommendations, still in draft form and open for public comment, that clarifies what the FDA expects to see in a generic application. Here is what the agency published, which products it covers, and why it matters for the telehealth companies and patients who rely on peptide medicines.

What the FDA published

The FDA released 17 revised draft product-specific guidances (PSGs) for peptide drug products. A PSG is the agency's product-by-product roadmap for generic development: it lays out the studies and data the FDA recommends a company submit to show that a proposed generic is bioequivalent to the reference (brand) product. These recommendations feed the abbreviated new drug application (ANDA), the route generic drugs take to approval.

In its statement, the FDA described the update as a meaningful evolution in how it assesses generic peptide drug products, drawing on years of regulatory experience with this class. The Federal Register notice (Docket No. FDA-2007-D-0369) frames the documents as recommendations on bioequivalence study design for ANDAs, developed through the process the FDA set out in its June 2010 guidance on bioequivalence recommendations for specific products.

Which peptide products are covered

According to the FDA, the revised guidances span peptide medicines across several therapeutic areas. The list the agency describes includes the following, grouped by use:

• Obesity and type 2 diabetes: GLP-1 and related peptide medicines, including semaglutide (marketed as Ozempic and Wegovy), tirzepatide (Mounjaro and Zepbound), and liraglutide (Victoza and Saxenda).
• Emergency low blood sugar: glucagon products, including dasiglucagon and glucagon rescue formulations.
• Bone health: teriparatide and calcitonin salmon, used in osteoporosis.
• Eye and rare diseases: pegcetacoplan and vosoritide.

The 17 count reflects individual product presentations rather than 17 separate active ingredients, because a single peptide can appear in more than one dosage form or strength. The GLP-1 entries are the ones most likely to draw attention, given the size of the weight-loss market and the ongoing supply and pricing debates around semaglutide and tirzepatide.

What a product-specific guidance actually does

A PSG is guidance, not an approval and not a rule. It tells a generic developer how the FDA thinks bioequivalence can be demonstrated for a specific drug, for example the type of study to run and the analytical data to submit. A company still has to conduct the work, file an ANDA, and clear the FDA's review before any generic can be sold. Guidance documents also represent the agency's current thinking and do not create legally binding requirements.

Peptides sit in a scientifically tricky middle ground. They are larger and more complex than typical small-molecule drugs but are still regulated as drugs (not biologics) when they meet the statutory definition. That complexity is why the FDA has been building out peptide-specific expectations rather than relying on generic small-molecule playbooks.

The scientific areas the revisions address

The FDA said the revised guidances update its recommendations across several areas that are central to showing a generic peptide is the same as its brand reference:

• How peptides made by recombinant, synthetic, or semi-synthetic methods should be submitted and characterized.
• Testing for innate immune response impurities, a safety concern specific to complex molecules.
• Thresholds for impurities in the finished product.
• Assessment of higher order structure, meaning the folded three-dimensional shape of the peptide.
• Assessment of biological activity.

Why this matters for GLP-1 and peptide access

Much of the telehealth market for weight loss and diabetes runs on GLP-1 medicines, and much of the debate over the past two years has centered on cost, insurance coverage, and compounded alternatives that filled shortage-driven gaps. A clearer generic pathway is one of the mechanisms that could, over time, expand lower-cost supply of these drugs through FDA-approved generics rather than through compounding. That is the longer-term significance of clarifying how generic semaglutide and tirzepatide applications should be built.

This announcement is upstream of any change patients would notice at the pharmacy. It shapes how future applications are prepared and reviewed. It is separate from the compounding questions that have dominated recent peptide news, including the FDA advisory committee vote on which peptides pharmacies may compound under the 503A bulks list.

What this does not mean

The guidances do not approve a generic version of Ozempic, Wegovy, Mounjaro, Zepbound, or any other named product, and they do not set a launch date. Whether and when a generic reaches the market depends on factors the guidances do not control, including remaining patents and regulatory exclusivity on the brand drugs, whether companies choose to file ANDAs, and whether those applications succeed in FDA review. Because the documents are drafts, the recommendations themselves can change before they are finalized.

This article is general information, not medical or legal advice. Patients with questions about a specific GLP-1 or peptide medication, including access, cost, or switching products, should talk with a licensed clinician or pharmacist and rely on the FDA's primary documents for the regulatory details.

Comment period and next steps

The FDA is accepting public comments on the draft guidances through September 28, 2026, and says it will consider comments submitted to the public docket before it works on final versions. The Federal Register entry is filed under Docket No. FDA-2007-D-0369. Separately, the agency said it is withdrawing its May 2021 guidance on highly purified synthetic peptides, which it now considers outdated, and plans to issue a revised version in 2026.